|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
21.02.25 - 12:33
|
MeiraGTx Announces The Lancet Publication of Data Demonstrating the Efficacy of rAAV8.hRKp.AIPL1 for the Treatment of Leber Congenital Amaurosis 4 (LCA4) Retinal Dystrophy (GlobeNewswire EN)
|
|
|
LONDON and NEW YORK, Feb. 21, 2025 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage genetic medicines company, today announced the publication of results from the first-in-human interventional study to treat children with AIPL1-associated severe retinal dystrophy. The data were published in The Lancet in a paper titled, "Gene therapy in children with AIPL1-associated severe retinal dystrophy: an open-label, first-in-human interventional study". This paper presents data from the first 4 children treated unilaterally with rAAV8.hRKp.AIPL1. A further 7 children with LCA4 were treated bilaterally with rAAV8.hRKp.AIPL1 demonstrating similarly remarkable effects on vision, with all 11 of the 11 children treated who were blind at birth now having visual acuity in the treated eyes....
|
|
|
|
|
|
|
|
|
|
|
|
|
10.01.25 - 14:06
|
Chemify Hires Biopharma Veteran Dr. Alastair Leighton as Chief Operating Officer (Business Wire)
|
|
|
Previously at MeiraGTx, GSK and Novartis, Dr. Leighton will help Chemify scale the company's operational capacity to meet demand for the design and synthesis of complex small molecules.GLASGOW, Scotland--(BUSINESS WIRE)--#Chemify--Chemify, a deep tech chemical science company combining chemistry, robotics and AI at scale to digitally design, discover and make new molecules, announced today that Dr. Alastair Leighton has joined as Chief Operating Officer (COO). With almost three decades in the biopharma industry working at leading global pharmaceutical companies, Dr. Leighton brings a wealth of experience in manufacturing, supply chain operations and commercial strategy.
“I'm excited to welcome Alastair to Chemify to help us with building and scaling our ability to make complex molecules on demand at scale for our partners using Chemputation,” said Dr. Lee Cronin, CEO of Chemify. “His expertise with large biopharmaceutical organizations will help us continue to meet the strong demand for consistent...
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
